David Calabrese of OptumRx Talks Biden's Interest of More Biosimilars in Market

August 16, 2021

In this second part of a two-part video series, Briana Contreras, associate editor of MHE caught up with MHE Editorial Advisory Board member David Calabrese, who is market president of Health Plans/PBMs at OptumRx. Calabrese shared his thoughts on the approval of the Alzheimer’s drug Aduhelm, as well as the Biden Administration's interest in putting more generics and biosimilars in the market.

The Generic, Biosimilar Medicine Industry Today and What it Can Become in The Next Decade

July 14, 2021

International Generic and Biosimilar Medicines Association recently released the report, "A Vision for the Global Generic and Biosimilar Medicines Industry,” covering the current global Generic and Biosimilar medicine industry, and released a vision of what the market will be in 2030 and how to achieve it.

Generic Drug Price Tags: Too High. And Too Low. Competition Can Help Create an In-Between.

July 13, 2021

Low prices and some gaming of regulations can drive out competitors and create monopolies that allow generic makers to jack up their prices. Experience has shown that it often takes multiple generics to achieve the promised-for downward pressure on prices.